Contact
Please use this form to send email to PR contact of this press release:
Vyome Therapeutics Begins Dosing in Phase 2 Trial of VB-1953 in Moderate to Severe Inflammatory Acne Vulgaris
TO:
Please use this form to send email to PR contact of this press release:
Vyome Therapeutics Begins Dosing in Phase 2 Trial of VB-1953 in Moderate to Severe Inflammatory Acne Vulgaris
TO: